Fluoxetine

Learn what this care may do. See what research says. Then check where to get care. A place may not be taking new patients.

See published Need uses

Identity

Fluoxetine (sold under brand names such as Prozac; this page cites a Lupin Fluoxetine Hydrochloride capsule label) is a prescription medicine. Its U.S. product labeling lists obsessive-compulsive disorder (OCD) among the conditions it is indicated to treat.

DailyMed fluoxetine hydrochloride label · checked Oct 7, 2026

Relationship: supports

Statement scope

Efficacy population: adults in two 13-week trials and pediatric patients 7 to 17 years of age in one 13-week trial
Formulation or format: tablets, for oral use
Indication: obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD)
Population: patients with Obsessive Compulsive Disorder (OCD)
Section code: 34067-9

Source collection coverage: country:US

Pointer: /passage/text

Supporting passage: Fluoxetine Tablets is indicated for the treatment of: Obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD). The efficacy of fluoxetine in OCD was demonstrated in two 13-week trials in adults and one 13-week trial in pediatric patients 7 to 17 years of age [see CLINICAL STUDIES (14.2)].

Open source

Why-linked

EveryOption includes fluoxetine for OCD because the DailyMed Fluoxetine Hydrochloride label’s Indications and Usage section names Obsessive Compulsive Disorder as a labeled indication for adults and for pediatric patients 7 to 17 years of age. That label statement was checked against this source. A clinical evidence assessment of how well fluoxetine works for OCD has not yet been published here.

DailyMed fluoxetine hydrochloride label · checked Oct 7, 2026

Relationship: supports

Statement scope

Efficacy population: adults in two 13-week trials and pediatric patients 7 to 17 years of age in one 13-week trial
Formulation or format: tablets, for oral use
Indication: obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD)
Population: patients with Obsessive Compulsive Disorder (OCD)
Section code: 34067-9

Source collection coverage: country:US

Pointer: /passage/text

Open source

Indication-quote

Obsessive Compulsive Disorder (OCD)

DailyMed fluoxetine hydrochloride label · checked Oct 7, 2026

Relationship: supports

Statement scope

Efficacy population: adults in two 13-week trials and pediatric patients 7 to 17 years of age in one 13-week trial
Formulation or format: tablets, for oral use
Indication: obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD)
Population: patients with Obsessive Compulsive Disorder (OCD)
Section code: 34067-9

Source collection coverage: country:US

Pointer: /passage/text

Open source

Scope

This page explains why the option appears and what the cited label supports. It does not set dosing, compare treatments, or report availability. Access information is not shown here.

DailyMed fluoxetine hydrochloride label · checked Oct 7, 2026

Relationship: supports

Statement scope

Efficacy population: adults in two 13-week trials and pediatric patients 7 to 17 years of age in one 13-week trial
Formulation or format: tablets, for oral use
Indication: obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD)
Population: patients with Obsessive Compulsive Disorder (OCD)
Section code: 34067-9

Source collection coverage: country:US

Pointer: /passage/text

Open source

Provenance

Cited source: DailyMed (U.S. National Library of Medicine) structured product label for Fluoxetine Hydrochloride capsules (Lupin Pharmaceuticals, Inc.), SET ID f274f102-67ec-46e7-b248-533be2e3003b, version 5, Indications and Usage. Hosting on DailyMed is not a license to republish the full label.

DailyMed fluoxetine hydrochloride label · checked Oct 7, 2026

Relationship: supports

Statement scope

Efficacy population: adults in two 13-week trials and pediatric patients 7 to 17 years of age in one 13-week trial
Formulation or format: tablets, for oral use
Indication: obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD)
Population: patients with Obsessive Compulsive Disorder (OCD)
Section code: 34067-9

Source collection coverage: country:US

Pointer: /passage/text

Open source

Label-safety-warning

The U.S. label for fluoxetine tablets carries a warning titled “Suicidal Thoughts and Behaviors”: in short-term studies, antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults. Those studies did not show an increased risk in people over age 24, and showed a reduced risk in people aged 65 and older. This summarizes the label’s warning; it is not medical advice, and decisions about this medicine belong with a prescriber.

DailyMed fluoxetine hydrochloride label · checked Oct 7, 2026

Relationship: supports the attributed label warning and its age-specific findings

Statement scope

Formulation or format: tablets, for oral use
Population: children, adolescents, and young adults in short-term studies; patients over age 24; patients aged 65 and older
Section code: 34066-1
Statement subject: antidepressants

Source collection coverage: country:US

Pointer: /passage/text

Supporting passage: Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see WARNINGS AND PRECAUTIONS (5.1)].

Open source

Published Oct 7, 2026Revision 4 · EveryOptionEnglish (United States)

Published Need uses

Select an exact Need to inspect its scoped research. These are the uses currently published on EveryOption; they do not establish every use of Fluoxetine or a personal recommendation.

4 published uses

Fluoxetine for Bulimia Nervosa
Published assessmentPublished Sep 20, 2026 · revision 1
Fluoxetine for Major Depressive Disorder
Published assessmentPublished Sep 20, 2026 · revision 1
Fluoxetine for Panic Disorder
Published assessmentPublished Sep 20, 2026 · revision 1
Fluoxetine for Obsessive-Compulsive Disorder
Not reviewed

Fluoxetine for Bulimia Nervosa

The research answer belongs to this exact Need and its published scope. It does not establish benefit for other uses of Fluoxetine.

Research suggests benefit in this exact scope

Published Sep 20, 2026 · revision 1

What research says

The retained fluoxetine label reports three multicenter studies for bulimia nervosa; this assessment does not determine personal suitability or compare fluoxetine with every alternative.

DailyMed fluoxetine hydrochloride label · checked Oct 16, 2026

Relationship: supports bounded conclusion

Statement scope

Jurisdiction: United States label
Need: Bulimia Nervosa
Population: source-defined study populations

Source collection coverage: country:US

Pointer: /sections/4

Supporting passage: The effectiveness of fluoxetine for the treatment of bulimia was demonstrated in two 8-week and one 16-week, multicenter, parallel-group studies of adult outpatients meeting DSM-III-R criteria for bulimia.

Open source

DailyMed fluoxetine hydrochloride label · checked Oct 16, 2026

Relationship: label-reported clinical studies for the Need

Statement scope

Jurisdiction: United States label
Need: Bulimia Nervosa
Population: source-defined study populations

Source collection coverage: country:US

Pointer: /sections/4

Open source

Read exact answer Explore Bulimia Nervosa options

Fluoxetine for Major Depressive Disorder

The research answer belongs to this exact Need and its published scope. It does not establish benefit for other uses of Fluoxetine.

Research suggests benefit in this exact scope

Published Sep 20, 2026 · revision 1

What research says

The retained fluoxetine label reports placebo-controlled studies for major depressive disorder; this assessment does not determine personal suitability or compare fluoxetine with every alternative.

DailyMed fluoxetine hydrochloride label · checked Oct 16, 2026

Relationship: supports bounded conclusion

Statement scope

Jurisdiction: United States label
Need: Major Depressive Disorder
Population: source-defined study populations

Source collection coverage: country:US

Pointer: /sections/4

Supporting passage: The efficacy of fluoxetine was studied in 5- and 6-week placebo-controlled trials with depressed adult and geriatric outpatients (≥ 18 years of age) whose diagnoses corresponded most closely to the DSM-III (currently DSM-IV) category of MDD.

Open source

DailyMed fluoxetine hydrochloride label · checked Oct 16, 2026

Relationship: label-reported clinical studies for the Need

Statement scope

Jurisdiction: United States label
Need: Major Depressive Disorder
Population: source-defined study populations

Source collection coverage: country:US

Pointer: /sections/4

Open source

Read exact answer Explore Major Depressive Disorder options

Fluoxetine for Panic Disorder

The research answer belongs to this exact Need and its published scope. It does not establish benefit for other uses of Fluoxetine.

Research suggests benefit in this exact scope

Published Sep 20, 2026 · revision 1

What research says

The retained fluoxetine label reports two randomized, placebo-controlled studies for panic disorder; this assessment does not determine personal suitability or compare fluoxetine with every alternative.

DailyMed fluoxetine hydrochloride label · checked Oct 16, 2026

Relationship: supports bounded conclusion

Statement scope

Jurisdiction: United States label
Need: Panic Disorder
Population: source-defined study populations

Source collection coverage: country:US

Pointer: /sections/4

Supporting passage: The effectiveness of fluoxetine in the treatment of Panic Disorder was demonstrated in 2 double-blind, randomized, placebo-controlled, multicenter studies of adult outpatients who had a primary diagnosis of Panic Disorder (DSM-IV), with or without agoraphobia.

Open source

DailyMed fluoxetine hydrochloride label · checked Oct 16, 2026

Relationship: label-reported clinical studies for the Need

Statement scope

Jurisdiction: United States label
Need: Panic Disorder
Population: source-defined study populations

Source collection coverage: country:US

Pointer: /sections/4

Open source

Read exact answer Explore Panic Disorder options

Fluoxetine for Obsessive-Compulsive Disorder

The research answer belongs to this exact Need and its published scope. It does not establish benefit for other uses of Fluoxetine.

Not reviewed. No current published assessment exists for this exact Treatment and Need. This does not establish benefit or no benefit.

DailyMed fluoxetine hydrochloride label · checked Oct 16, 2026

Relationship: labeled indication

Statement scope

Formulation or format: tablets (product labeled Fluoxetine Hydrochloride capsule; Indications and Usage text refers to Fluoxetine Tablets; 60-mg scored tablet dosage form)
Indication: Obsessive Compulsive Disorder (OCD)
Population: adults and pediatric patients 7 to 17 years of age with Obsessive Compulsive Disorder (OCD), as labeled
Section code: 34067-9

Source collection coverage: country:US

Pointer: /sections/1

Open source

Read exact answer Explore Obsessive-Compulsive Disorder options

Next: check access

Research and local availability are different facts. Add a place to see known, source-backed access options for Fluoxetine.

Find access

See something wrong? Tell us. Your note is private. We check sources before we change this page.